|
Mutation Information
|
Mutation Site
|
S143T |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.S143T+s.F134L |
|
Amino acid_Mutation
|
T556A |
|
Genotype/Subtype
|
A |
|
Relevant Drug
|
lamivudine (LAM) |
|
Country
|
Japan |
Literature Information
|
PubMed PMID
|
25786446
|
|
Disease
|
HBV-HIV coinfection
|
|
Published Year
|
2015 |
|
Journal
|
Internal medicine (Tokyo, Japan) |
|
Title
|
Hepatitis B e antigen and hepatitis B surface antigen seroclearance with the emergence of lamivudine-associated and core mutations following CD4 elevation in a patient with hepatitis B and HIV. |
|
Author
|
Honda T,Ishigami M,Luo F,Ishizu Y,Kuzuya T,Hayashi K,Itoh A,Hirooka Y,Ishikawa T,Nakano I,Katano Y,Goto H |
|
Evidence
|
A full-length HBV DNA analysis indicated that HBsAg had been lost after the development of the rtS143T mutation, which corresponded to the emergence of the sF134L and core mutations.
|
|
|
HBV Mutation Detail Information